OncologyEducation

During #ColorectalCancerAwarenessMonth, stay current on evolving GI oncology data. Join the Best of GU & GI Cancers Conference 2026. 📄 Download the full agenda: bit.ly/40b5LPY #GIOncology #CancerEducation #CME

Don’t miss the Best of GU & GI Cancers Conference 2026. 📅 April 17, 2026 Expert-led updates in GU & GI oncology Clinical insights you can apply immediately Register now: bit.ly/3OvjDC4 #GUCancers #GICancers #Oncology

Advancing MDS Care 🩸 New Expert Brief & Infographic translating emerging trial outcomes into clinical practice. Stay current on key MDS updates. Read more: bit.ly/3OUaNOc #MDS #Hematology #Oncology

🇨🇦 #CMC26 is back! The 20th Canadian Melanoma Conference 🗓 Feb 26–28, 2026 📍 Vancouver (In-person + virtual) Join Canada’s leading experts to explore the latest advances in melanoma care. Register: oncologyeducation.com/all-events/ #Melanoma #Oncology

New infographic 📊 RELATIVITY-047 4-year update highlights long-term efficacy & safety of nivolumab + relatlimab in advanced melanoma. Explore OS, PFS, response durability & AEs in one clear visual. 🔗 ow.ly/hIJA50YbVRn #Melanoma #Oncology #Immunotherapy

Episode 16 is out 🎧✨ Dive into Targeting HER2 Alterations in NSCLC with Dr. Melosky, hosted by Dr. Kassam. 🎙️ Listen now on MedOncNow ow.ly/2JNs50YbVf8 #OncologyEducation #MedOncNow #NSCLC #HER2 #OncologyPodcast #MedicalEducation

World Cancer Day reminds us that advancing cancer care is a global effort. Proud to support healthcare professionals with evidence-based education that helps improve outcomes for patients everywhere. 💙 #WorldCancerDay #OncologyEducation #CancerCare

🎙️ New #MedOncNow episode is live! Treatment selection in advanced NSCLC (without AGA & EGFR+) with Dr. Natasha Leighl, hosted by Dr. Shaquil Kassam. 🎧 Listen now 👉 ow.ly/gsmG50Y07Mi

📊 New infographic alert! A visual summary of the RALU study exploring sequential use of radium-223 and lutetium-177 in mCRPC. Download here 👇 ow.ly/PwE450XZMts #Oncology #mCRPC #Infographic #MedicalEducation

🎙️ MedOncNow – Episode 14: Sequencing in Advanced Colorectal Cancer with Dr. Scott Berry. Tune in for insights that matter! 🎧☕ Listen now! ow.ly/uvxJ50XNJiG

New infographic drop! Explore how FLT3 mutations and clonal evolution drive relapse in AML — and why re-testing is essential for targeted therapy decisions. 🔽 Download now: ow.ly/Wxy650XqBnH #AML #FLT3 #OncologyEducation #TargetedTherapy

Early bird rates expiring soon! Join us at the 20th Canadian Melanoma Conference in Vancouver as global experts share the latest advancements in melanoma diagnosis and treatment. 📍Fairmont Hotel Vancouver | Feb 26–28, 2026 Save on tickets: ow.ly/BYpn50WKnRP #CMC26

Unexpected outcome! Dr. Kim Chi reports lutetium's response (1 discontinuation vs 15 for docetaxel), but overall survival favored docetaxel. High crossover to lutetium shows need for therapy analysis! #ESMO25 #ProstateCancer #LuPSMA #Docetaxel #ClinicalTrial #Crossover

Historic milestone! @TonyMok9 reports median Overall Survival of 81 months with Alectinib in ALK+ NSCLC. Duration of Response: 42 months! #ESMO25 #LungCancer #ALKTKI #ALEXStudy #Alectinib #StandardOfCare

@JeanneTie reports ctDNA de-escalation is feasible, cutting chemotherapy and improving safety. Non-inferiority was narrowly missed, but outcomes support ctDNA-guided risk discussions. #ESMO25 #ctDNA #ChemoDeEscalation #ColorectalCancer #PrecisionOncology

Featuring @drenriquegrande : The DISCO trial shows that immunotherapy can de-escalate cycles and drug amounts, reducing toxicity and cost! #ESMO25 #ClinicalTrials #DeEscalation #Immunotherapy #Oncology

Day 2 of #ESMO25 highlights! ✅ 81-month lung cancer survival ✅ 1/10th-dose immunotherapy ✅ Chemo-free, kidney-sparing strategies. Stay tuned for more from Berlin! 🇩🇪 #ESMO25 #Oncology #ClinicalTrials #CancerInnovation #OncologyEducation

Groundbreaking data from Dr. Atul Batra shows that a 1/10th dose of Pembrolizumab matches pCR rates of KEYNOTE-522, improving treatment access for 90% of low- and middle-income patients. #ESMO25 #GlobalOncology #Pembrolizumab #HealthEquity #CancerAccess #CheckpointInhibitors

"No survival benefit! Dr. Judith Quik highlights the Periscope II study: CRS + HIPEC offered no improvement over systemic therapy for gastric cancer with limited peritoneal disease. Toxicity not justified!" #ESMO25 #GastricCancer #PeriscopeII #HIPEC #OncologyResearch

Major Phase III results! Dr. Sara Hurvitz on VICTORIA-1 at #ESMO25 shows improved PFS in HR+ advanced breast cancer. #BreastCancer #PFS #ClinicalTrial #HRPositive #Oncology